Vasomune Therapeutics completed enrollment in AV001-004, a randomized, double-blind, placebo-controlled Phase 2a study evaluating pegevongitide (AV-001) in hospitalized pneumonia patients requiring supplemental oxygen. The trial program is Fast Track-designated by the FDA for the prevention and treatment of moderate-to-severe ARDS associated with respiratory infection, and the company indicated it will move into data review, site closeout, and database lock activities.